Dr. Charles Cantor is co-founder, and retired Chief Scientific Officer at SEQUENOM, Inc., the leading provider of noninvasive prenatal testing. He consults for a number of biotech companies including Simcere/Bioscikin (China), Star-Array (Singapore), Edico Genomics (USA), Innovative Biosciences (China), Agena Biosciences (USA), Strand Life Sciences (India), Trovagene (USA), Ana Jema (China), ProdermIQ (USA), Armonica (USA), Anchor DX (China), My Genome Box, a subsidiary of EOne (Korea), Genetic intelligence (USA, Apostle (USA), In Silico Biology (Russia, USA), and ARNA Genomics (Russia) and he is co-founder and executive director of Retrotope (USA), a clinical stage pharmaceutical company.
Dr. Cantor was educated in chemistry at Columbia College (AB, 1963) and UC Berkeley (PhD, 1966). He became a full professor of chemistry at Columbia University at the age of 29. Dr. Cantor has held academic and leadership positions at Columbia and several other distinguished American universities, but for the past 20 years he has focused his efforts in biotechnology companies. Dr. Cantor is currently professor emeritus of Biomedical Engineering and of Pharmacology at Boston University. He is adjunct professor of Molecular Biology at the Scripps Institute for Research, distinguished adjunct professor of Physiology and Biophysics at UC Irvine and adjunct professor at the Moscow institute of Physics and Technology.
Dr. Cantor has been granted more than 60 US patents and, with Paul Schimmel, wrote a three-volume textbook on biophysical chemistry that has remained the standard in this field for more than 35 years. He has published more than 450 peer-reviewed articles, and is a member of the U.S. National Academy of Sciences and The National Academy of Inventors. His major scientific accomplishments include the development of pulsed field electrophoresis, immuno-PCR, affinity capture electrophoresis, the earliest uses of FRET to characterize distances in protein complexes and nucleic acids, the standard methods for assaying and purifying microtubule protein, various applications of nucleic acid mass spectrometry, and methods for noninvasive prenatal diagnostics. He is also considered to be one of the founders of the new field of synthetic biology.
In the past decade Dr. Cantor has focused his attention on developing rational and cost-effective approaches to preventive and personalized medicine. This includes (1) liquid biopsies (Agena Biosciences, Trovagene, Innovative Biociences, Anchor Dx, ARNA, Apostle) that could detect age-related disease pathology earlier and thus allow for more effective intervention, (2) DNA testing in minutes suitable for use in emergency rooms and operating theaters (Star-Array) and (3) deuterated lipids (Retrotope) that show great promise at reducing the oxidative damage processes that play a central role in many age-related diseases.
Orenburgskii trakt, 138, build.9
Kazan, Republic of Tatarstan
+7 (843) 237-84-69
© 2018 ICO KAZAN SUMMIT
ALL RIGHTS RESERVED.
NO PART OF THIS WEBSITE/DOCUMENT
MAY BE REPRODUCED OR TRANSMITTED
IN ANY FORM OR BY ANY MEANS
WITHOUT THE PRIOR WRITTEN